Nested Therapeutics, a precision oncology company targeting previously undruggable cancer targets, closed on a $90 million Series A financing, bringing total financing to $125 million since its inception in 2021.
https://www.pharmalive.com/wp-content/uploads/2022/10/Klaus-Hoeflich.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-10-06 09:12:442022-10-06 09:12:44Nested Therapeutics raises $90M to crack new proteins in precision oncology